Investment ThemesDetailed Quotes
CAR-T Therapy
Watchlist
- 1077.748
- +10.769+1.01%
Close Jul 26 16:00 ET
1081.879High1069.415Low
1071.113Open1066.979Pre Close64.37MVolume10Rise17.07P/E (Static)3.91BTurnover--Flatline0.45%Turnover Ratio1.16TMarket Cap--Fall1.14TFloat Cap
Constituent Stocks: 10Top Rising: ADAP+6.92%
PFE us at resistance, 30.70
Earnings soon, stars aligned
above 50 EMA
When PFE turns, it will move hard and fast. a lot of pressure has been built up over the 1.5-year drop.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US)$ , adding a layer of clout to the R&D behind the prospective treatment.
Sneaking on the radar on a red day.
No comment yet